The New York Statewide HCCN (NYS-HCCN) at CHCANYS
HCCN Infographic

Established in 2012, the New York Statewide Health Center Controlled Network (NYS-HCCN) is one of forty-nine HRSA funded networks that work together to strengthen and leverage health information technology (HIT).

Benefits & Eligibility
AmeriCorps Members

CHCANYS Public Health AmeriCorps is a partnership and collaboration between CHCANYS, the New York State Commission on National and Community Service, AmeriCorps, and the CDC.

Resources on workforce & human resources
Workforce

Various online resources compiled to provide health centers with valuable information and training and technical assistance on workforce, human resources, and National Health Services Corps Programs and other health workforce related resources.

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
RESOURCES AND RELATED EVENTS
Data Analytics

Data Analytics is the act of extracting and organizing raw data in order to identify patterns and make inferences.

Current:

HCCN Infographic
Join CHCANYS AmeriCorps
Workforce
UDS+

HEALTH ADVISORY: Additional mRNA COVID-19 vaccine dose after an initial 2-dose COVID-19 mRNA vaccine series for immunocompromised people.

SUMMARY

  • The U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for the available mRNA vaccines to include the option of administering an additional dose of an mRNA vaccine to immunocompromised individuals.
  • The Advisory Committee on Immunization Practices (ACIP) made an interim recommendation for an additional dose of Pfizer and Moderna COVID-19 vaccine for people with defined moderate to severe immunosuppression, at least 28 days after the completion of an initial 2-dose primary mRNA COVID-19 vaccine series. There is no maximum time period for when a third dose can be given after the second dose.
  • At this time, an additional dose of COVID-19 vaccine is not recommended for any other group.
  • Currently, there are insufficient data to support the use of an additional mRNA COVID-19 vaccine dose after a single-dose Janssen COVID-19 vaccination series in immunocompromised people.
  • The age groups authorized for an additional dose remain the same as those for the primary mRNA COVID-19 dose series (Pfizer: aged ≥12 years or Moderna: aged ≥18 years).
  • Serologic testing to assess immune response to vaccination is not recommended.
  • The reactogenicity profile of the additional dose was similar to prior doses of mRNA COVID-19 vaccines.
  • Although certain chronic medical conditions, such as diabetes and cardiovascular disease, may be associated with varying degrees of immune deficit, these conditions are not considered moderately to severely immunosuppressive and thus a third dose of vaccine is not recommended at this time.
  • Immunocompromised individuals should be informed about the potential for a reduced immune response to vaccination, even after a third dose, and the need to continue other COVID-19 prevention measures.
  • Regardless of vaccination status, providers should discuss monoclonal antibody treatment options with their immunocompromised patients and encourage them to seek care right away if they have COVID-19 symptoms or an exposure to someone confirmed with COVID-19.

Click here to access the full health advisory by NYSDOH. Click here to access NYSDOH’s Guidance for the New York State COVID-19 Vaccination Program. Click here to access DOHMH Vaccine Information for Providers.

Published on